2018 | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy | AAPS JOURNAL |
2022 | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
| NATURE COMMUNICATIONS |
2011 | Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis.
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
2013 | Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool | ANNALS OF SURGICAL ONCOLOGY |
2019 | Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
| CANCER RESEARCH AND TREATMENT |
2021 | Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis | EUROPEAN JOURNAL OF CANCER |
2021 | Detection of asymptomatic recurrence improves survival of gastric cancer patients
| CANCER MEDICINE |
2020 | Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)-a randomized controlled trial | SUPPORTIVE CARE IN CANCER |
2012 | External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer
| ANNALS OF ONCOLOGY |
2013 | Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer | JOURNAL OF CLINICAL ONCOLOGY |
2010 | Green tea consumption and stomach cancer risk: a meta-analysis
| EPIDEMIOLOGY AND HEALTH |
2023 | Impact of Coronavirus Disease 2019 on Gastric Cancer Diagnosis and Stage: A Single-Institute Study in South Korea
| JOURNAL OF GASTRIC CANCER |
2019 | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer | ONCOLOGIST |
2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | JOURNAL OF CLINICAL ONCOLOGY |
2014 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
2019 | Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer | EUROPEAN JOURNAL OF CANCER |
2018 | Reconsideration of sample size and power calculation for overall survival in cancer clinical trials
| CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS |
2018 | Screening audit' as a quality assurance tool in good clinical practice compliant research environments
| BMC MEDICAL ETHICS |
2024 | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | GASTRIC CANCER |
2019 | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
| CANCER RESEARCH AND TREATMENT |
2023 | Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer | JOURNAL OF CLINICAL ONCOLOGY |